Scalper1 News
British drugmaker Shire (SHPG) agreed to pay $5.9 billion in cash for orphan-drug specialist Dyax (DYAX) Monday, sending the latter’s stock up sharply in early trading. Shire will pay $37.30 a share for Dyax, a premium of nearly 36% on Dyax’s Friday closing price. The deal includes a contingent value right (CVR) of $4 a share, or $646 million total, on Dyax’s drug candidate DX-2930, which is about to enter phase-three testing for hereditary Scalper1 News
Scalper1 News